Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsCancer

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1178472

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1178472

Global Ovarian Cancer Diagnostics Market - Industry Trends and Forecast to 2030

PUBLISHED:
PAGES: 202 Pages
DELIVERY TIME: Inquiry
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 4800
PDF (Enterprise License) - Printable/Downloadable
USD 7000

Add to Cart

Description

Table of Contents

List of Tables

The global ovarian cancer diagnostics market is projected to register a substantial CAGR of 7.0% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Global Ovarian Cancer Diagnostics Market- By Product Type (Instruments, Kits and Reagents), Procedure Type (Biopsy Test, Medical Imaging Test, Blood Markers Testing, Genetic Testing), Cancer Type (Germ Cell, Epithelial Tumor, Stromal Cell Tumor), End User (Cancer Diagnostic Centers, Hospital Laboratories, Research Institutes, Others), Country (U.S., Canada, Mexico, Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Kuwait, and Rest of Middle East and Africa) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of global ovarian cancer diagnostics market are:

Growing ovarian cancer awareness

Improved diagnostic processes and techniques

Increase in number of new cases every year

Improved imaging techniques

Market Players:

The major companies which are dealing in the global ovarian cancer diagnostics market are listed below:

F. Hoffmann-la roche ltd

Tosoh india pvt. Ltd.

Luminex corporation

Quest diagnostics incorporated

Thermo fisher scientific Inc.

Ngenebio

Abbott

Siemens healthcare private limited

Myriad genetics Inc.

Bio-rad laboratories, Inc.

R&d systems, Inc.

Foundation medicine, Inc.

Biosupply ltd

Lcm genect srl

Inex innovate private limited

Abcam plc.

Monobind Inc.

Fujirebio

Mp biomedicals

Biovision Inc.

Boster biological technology

Biogenix Inc. Pvt. Ltd.

Genway biotech

Lifespan biosciences, Inc

Show more

TABLE OF CONTENTS

1 INTRODUCTION 21

  • 1.1 OBJECTIVES OF THE STUDY 21
  • 1.2 MARKET DEFINITION 21
  • 1.3 OVERVIEW OF GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET 21
  • 1.4 LIMITATIONS 22
  • 1.5 MARKETS COVERED 23

2 MARKET SEGMENTATION 25

  • 2.1 MARKETS COVERED 25
  • 2.2 GEOGRAPHICAL SCOPE 26
  • 2.3 YEARS CONSIDERED FOR THE STUDY 27
  • 2.4 CURRENCY AND PRICING 27
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 28
  • 2.6 MULTIVARIATE MODELLING 31
  • 2.7 PRODUCT TYPE LIFELINE CURVE 31
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 32
  • 2.9 DBMR MARKET POSITION GRID 33
  • 2.10 MARKET TESTING TYPE COVERAGE GRID 34
  • 2.11 VENDOR SHARE ANALYSIS 35
  • 2.12 SECONDARY SOURCES 36
  • 2.13 ASSUMPTIONS 36

3 EXECUTIVE SUMMARY 37

4 PREMIUM INSIGHTS 40

  • 4.1 PESTEL ANALYSIS 43
  • 4.2 PORTER'S FIVE FORCES 44
  • 4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS 45

5 INDUSTRY INSIGHTS 46

  • 5.1 CONCLUSION 47

6 REGULATIONS OF THE GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET 48

7 MARKET OVERVIEW 50

  • 7.1 DRIVERS 52
    • 7.1.1 GROWING OVARIAN CANCER AWARENESS 52
    • 7.1.2 IMPROVED DIAGNOSTIC PROCESSES AND TECHNIQUES 52
    • 7.1.3 INCREASE IN NUMBER OF NEW CASES EVERY YEAR 53
    • 7.1.4 IMPROVED IMAGING TECHNIQUES 53
  • 7.2 RESTRAINS 54
    • 7.2.1 HIGH COST OF DIAGNOSIS 54
    • 7.2.2 ADVERSE EFFECTS OF THE TREATMENT 54
  • 7.3 OPPORTUNITIES 55
    • 7.3.1 INCREASING HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 55
    • 7.3.2 GOVERNMENT INITIATIVES TOWARDS CANCER DIAGNOSTICS 55
  • 7.4 CHALLENGES 56
    • 7.4.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS 56
    • 7.4.2 LACK OF SKILLED PROFESSIONALS 57

8 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 58

  • 8.1 OVERVIEW 59
  • 8.2 INSTRUMENTS 62
  • 8.3 KITS AND REAGENTS 63

9 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE 64

  • 9.1 OVERVIEW 65
  • 9.2 BLOOD MARKERS TESTING 68
  • 9.3 MEDICAL IMAGING TEST 69
  • 9.4 BIOPSY TEST 70
  • 9.5 GENETIC TESTING 71

10 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 72

  • 10.1 OVERVIEW 73
  • 10.2 EPITHELIAL TUMOR 76
  • 10.3 GERM CELL 76
  • 10.4 STROMAL CELL TUMOR 77

11 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER 78

  • 11.1 OVERVIEW 79
  • 11.2 CANCER DIAGNOSTIC CENTERS 82
  • 11.3 HOSPITAL LABORATORIES 82
  • 11.4 RESEARCH INSTITUTES 83
  • 11.5 OTHERS 84

12 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY 85

  • 12.1 OVERVIEW 86
  • 12.2 NORTH AMERICA 91
    • 12.2.1 U.S. 97
    • 12.2.2 CANADA 98
    • 12.2.3 MEXICO 99
  • 12.3 EUROPE 100
    • 12.3.1 GERMANY 106
    • 12.3.2 FRANCE 107
    • 12.3.3 U.K. 108
    • 12.3.4 ITALY 109
    • 12.3.5 SPAIN 110
    • 12.3.6 RUSSIA 111
    • 12.3.7 TURKEY 112
    • 12.3.8 BELGIUM 113
    • 12.3.9 NETHERLANDS 114
    • 12.3.10 SWITZERLAND 115
    • 12.3.11 REST OF EUROPE 116
  • 12.4 ASIA-PACIFIC 117
    • 12.4.1 JAPAN 123
    • 12.4.2 CHINA 124
    • 12.4.3 SOUTH KOREA 125
    • 12.4.4 INDIA 126
    • 12.4.5 AUSTRALIA 127
    • 12.4.6 SINGAPORE 128
    • 12.4.7 THAILAND 129
    • 12.4.8 MALAYSIA 130
    • 12.4.9 INDONESIA 131
    • 12.4.10 PHILIPPINES 132
    • 12.4.11 REST OF ASIA-PACIFIC 133
  • 12.5 SOUTH AMERICA 134
    • 12.5.1 BRAZIL 140
    • 12.5.2 ARGENTINA 141
    • 12.5.3 REST OF SOUTH AMERICA 142
  • 12.6 MIDDLE EAST AND AFRICA 143
    • 12.6.1 SOUTH AFRICA 149
    • 12.6.2 SAUDI ARABIA 150
    • 12.6.3 U.A.E 151
    • 12.6.4 EGYPT 152
    • 12.6.5 ISRAEL 153
    • 12.6.6 REST OF MIDDLE EAST AND AFRICA 154

13 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 155

  • 13.1 COMPANY SHARE ANALYSIS: GLOBAL 155
  • 13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 156
  • 13.3 COMPANY SHARE ANALYSIS: EUROPE 157
  • 13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 158

14 SWOT ANALYSIS 159

15 COMPANY PROFILE 160

  • 15.1 F. HOFFMANN-LA ROCHE LTD 160
    • 15.1.1 COMPANY SNAPSHOT 160
    • 15.1.2 REVENUE ANALYSIS 161
    • 15.1.3 COMPANY SHARE ANALYSIS 161
    • 15.1.4 PRODUCT PORTFOLIO 161
    • 15.1.5 RECENT DEVELOPMENTS 162
  • 15.2 TOSOH INDIA PVT. LTD. 163
    • 15.2.1 COMPANY SNAPSHOT 163
    • 15.2.2 COMPANY SHARE ANALYSIS 163
    • 15.2.3 PRODUCT PORTFOLIO 164
    • 15.2.4 RECENT DEVELOPMENT 164
  • 15.3 LUMINEX CORPORATION (2022) 165
    • 15.3.1 COMPANY SNAPSHOT 165
    • 15.3.2 COMPANY SHARE ANALYSIS 165
    • 15.3.3 PRODUCT PORTFOLIO 166
    • 15.3.4 RECENT DEVELOPMENT 166
  • 15.4 QUEST DIAGNOSTICS INCORPORATED (2022) 167
    • 15.4.1 COMPANY SNAPSHOT 167
    • 15.4.2 REVENUE ANALYSIS 167
    • 15.4.3 COMPANY SHARE ANALYSIS 168
    • 15.4.4 PRODUCT PORTFOLIO 168
    • 15.4.5 RECENT DEVELOPMENTS 169
  • 15.5 THERMO FISHER SCIENTIFIC INC 170
    • 15.5.1 COMPANY SNAPSHOT 170
    • 15.5.2 REVENUE ANALYSIS 170
    • 15.5.3 COMPANY SHARE ANALYSIS 171
    • 15.5.4 PRODUCT PORTFOLIO 171
    • 15.5.5 RECENT DEVELOPMENT 171
  • 15.6 ABBOTT 172
    • 15.6.1 COMPANY SNAPSHOT 172
    • 15.6.2 REVENUE ANALYSIS 173
    • 15.6.3 PRODUCT PORTFOLIO 173
    • 15.6.4 RECENT DEVELOPMENT 173
  • 15.7 ABCAM PLC (2022) 174
    • 15.7.1 COMPANY SNAPSHOT 174
    • 15.7.2 REVENUE ANALYSIS 175
    • 15.7.3 PRODUCT PORTFOLIO 175
    • 15.7.4 1.7.4 RECENT DEVELOPMENT 175
  • 15.8 BIOSUPPLY LTD 176
    • 15.8.1 COMPANY SNAPSHOT 176
    • 15.8.2 PRODUCT PORTFOLIO 176
    • 15.8.3 RECENT DEVELOPMENT 176
  • 15.9 BIO-RADBIO LABORATORIES 177
    • 15.9.1 COMPANY SNAPSHOT 177
    • 15.9.2 REVENUE ANALYSIS 178
    • 15.9.3 PRODUCT PORTFOLIO 178
    • 15.9.4 RECENT DEVELOPMENTS 179
  • 15.10 BIOVISION INC. 180
    • 15.10.1 COMPANY SNAPSHOT 180
    • 15.10.2 PRODUCT PORTFOLIO 180
    • 15.10.3 RECENT DEVELOPMENT 180
  • 15.11 BIOGENIX INC. PVT. LTD. 181
    • 15.11.1 COMPANY SNAPSHOT 181
    • 15.11.2 PRODUCT PORTFOLIO 181
    • 15.11.3 RECENT DEVELOPMENT 181
  • 15.12 BOSTER BIOLOGICAL TECHNOLOGY 182
    • 15.12.1 COMPANY SNAPSHOT 182
    • 15.12.2 PRODUCT PORTFOLIO 182
    • 15.12.3 RECENT DEVELOPMENT 182
  • 15.13 FOUNDATION MEDICINE 183
    • 15.13.1 COMPANY SNAPSHOT 183
    • 15.13.2 PRODUCT PORTFOLIO 183
    • 15.13.3 RECENT DEVELOPMENT 183
  • 15.14 FUJIREBIO 184
    • 15.14.1 COMPANY SNAPSHOT 184
    • 15.14.2 PRODUCT PORTFOLIO 184
    • 15.14.3 RECENT DEVELOPMENT 184
  • 15.15 GENWAY BIOTECH 185
    • 15.15.1 COMPANY SNAPSHOT 185
    • 15.15.2 PRODUCT PORTFOLIO 185
    • 15.15.3 RECENT DEVELOPMENT 185
  • 15.16 INEX INNOVATIVE PRIVATE LIMITED 186
    • 15.16.1 COMPANY SNAPSHOT 186
    • 15.16.2 PRODUCT PORTFOLIO 186
    • 15.16.3 RECENT DEVELOPMENT 186
  • 15.17 LCM GENETIC SRL 187
    • 15.17.1 COMPANY SNAPSHOT 187
    • 15.17.2 PRODUCT PORTFOLIO 187
    • 15.17.3 RECENT DEVELOPMENT 187
  • 15.18 LIFESPAN BIOSCIENCES, INC 188
    • 15.18.1 COMPANY SNAPSHOT 188
    • 15.18.2 PRODUCT PORTFOLIO 188
    • 15.18.3 RECENT DEVELOPMENTS 189
  • 15.19 MP BIOMEDICALS 190
    • 15.19.1 COMPANY SNAPSHOT 190
    • 15.19.2 PRODUCT PORTFOLIO 190
    • 15.19.3 RECENT DEVELOPMENT 190
  • 15.20 MONOBIND INC. 191
    • 15.20.1 COMPANY SNAPSHOT 191
    • 15.20.2 PRODUCT PORTFOLIO 191
    • 15.20.3 RECENT DEVELOPMENT 191
  • 15.21 MYRIAD GENETICS, INC. 192
    • 15.21.1 COMPANY SNAPSHOT 192
    • 15.21.2 REVENUE ANALYSIS 192
    • 15.21.3 PRODUCT PORTFOLIO 193
    • 15.21.4 RECENT DEVELOPMENT 193
  • 15.22 NGENEBIO 194
    • 15.22.1 COMPANY SNAPSHOT 194
    • 15.22.2 PRODUCT PORTFOLIO 194
    • 15.22.3 RECENT DEVELOPMENTS 195
  • 15.23 R&D SYSTEMS, INC. 196
    • 15.23.1 COMPANY SNAPSHOT 196
    • 15.23.2 PRODUCT PORTFOLIO 196
    • 15.23.3 RECENT DEVELOPMENT 196
  • 15.24 SIEMENS MEDICAL SOLUTIONS 197
    • 15.24.1 COMPANY SNAPSHOT 197
    • 15.24.2 REVENUE ANALYSIS 197
    • 15.24.3 PRODUCT PORTFOLIO 198
    • 15.24.4 RECENT DEVELOPMENT 198

16 QUESTIONNAIRE 199

17 RELATED REPORTS 202

Show more

LIST OF TABLES

  • TABLE 1 24-MONTH EPISODE-OF-CARE COSTS FOR EARLY-STAGE AND LATE-STAGE CANCERS BY PAYER (USD BILLION) 54
  • TABLE 2 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 61
  • TABLE 3 GLOBAL INSTRUMENTS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 62
  • TABLE 4 GLOBAL KITS AND REAGENTS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 63
  • TABLE 5 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 67
  • TABLE 6 GLOBAL BLOOD MARKERS TESTING IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 68
  • TABLE 7 GLOBAL MEDICAL IMAGING TEST IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 69
  • TABLE 8 GLOBAL BIOPSY TEST IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 70
  • TABLE 9 GLOBAL GENETIC TESTING IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 71
  • TABLE 10 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 75
  • TABLE 11 GLOBAL EPITHELIAL TUMOR IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 76
  • TABLE 12 GLOBAL GERM CELL IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 77
  • TABLE 13 GLOBAL STROMAL CELL TUMOR IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 77
  • TABLE 14 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 81
  • TABLE 15 GLOBAL CANCER DIAGNOSTIC CENTERS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
  • TABLE 16 GLOBAL HOSPITAL LABORATORIES IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
  • TABLE 17 GLOBAL RESEARCH INSTITUTES IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
  • TABLE 18 GLOBAL OTHERS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 84
  • TABLE 19 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
  • TABLE 20 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 95
  • TABLE 21 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 95
  • TABLE 22 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 95
  • TABLE 23 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 95
  • TABLE 24 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 96
  • TABLE 25 U.S. OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 97
  • TABLE 26 U.S. OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 97
  • TABLE 27 U.S. OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 97
  • TABLE 28 U.S. OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 97
  • TABLE 29 CANADA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 98
  • TABLE 30 CANADA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 98
  • TABLE 31 CANADA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 98
  • TABLE 32 CANADA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 98
  • TABLE 33 MEXICO OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 99
  • TABLE 34 MEXICO OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 99
  • TABLE 35 MEXICO OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 99
  • TABLE 36 MEXICO OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 99
  • TABLE 37 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 104
  • TABLE 38 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 104
  • TABLE 39 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 104
  • TABLE 40 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 105
  • TABLE 41 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 105
  • TABLE 42 GERMANY OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 106
  • TABLE 43 GERMANY OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 106
  • TABLE 44 GERMANY OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 106
  • TABLE 45 GERMANY OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 106
  • TABLE 46 FRANCE OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 107
  • TABLE 47 FRANCE OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 107
  • TABLE 48 FRANCE OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 107
  • TABLE 49 FRANCE OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 107
  • TABLE 50 U.K. OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 108
  • TABLE 51 U.K. OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 108
  • TABLE 52 U.K. OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 108
  • TABLE 53 U.K. OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 108
  • TABLE 54 ITALY OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 109
  • TABLE 55 ITALY OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 109
  • TABLE 56 ITALY OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 109
  • TABLE 57 ITALY OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 109
  • TABLE 58 SPAIN OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 110
  • TABLE 59 SPAIN OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 110
  • TABLE 60 SPAIN OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 110
  • TABLE 61 SPAIN OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 110
  • TABLE 62 RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 111
  • TABLE 63 RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 111
  • TABLE 64 RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 111
  • TABLE 65 RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 111
  • TABLE 66 TURKEY OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 112
  • TABLE 67 TURKEY OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 112
  • TABLE 68 TURKEY OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 112
  • TABLE 69 TURKEY OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 112
  • TABLE 70 BELGIUM OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 113
  • TABLE 71 BELGIUM OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 113
  • TABLE 72 BELGIUM OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 113
  • TABLE 73 BELGIUM OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 113
  • TABLE 74 NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 75 NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 76 NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 77 NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 114
  • TABLE 78 SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 115
  • TABLE 79 SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 115
  • TABLE 80 SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 115
  • TABLE 81 SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 115
  • TABLE 82 REST OF EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 116
  • TABLE 83 REST OF EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 116
  • TABLE 84 REST OF EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 116
  • TABLE 85 REST OF EUROPE OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 116
  • TABLE 86 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 121
  • TABLE 87 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 121
  • TABLE 88 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 121
  • TABLE 89 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 122
  • TABLE 90 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 122
  • TABLE 91 JAPAN OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 123
  • TABLE 92 JAPAN OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 123
  • TABLE 93 JAPAN OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 123
  • TABLE 94 JAPAN OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 123
  • TABLE 95 CHINA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 124
  • TABLE 96 CHINA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 124
  • TABLE 97 CHINA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 124
  • TABLE 98 CHINA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 124
  • TABLE 99 SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 125
  • TABLE 100 SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 125
  • TABLE 101 SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 125
  • TABLE 102 SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 125
  • TABLE 103 INDIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 126
  • TABLE 104 INDIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 126
  • TABLE 105 INDIA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 126
  • TABLE 106 INDIA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 126
  • TABLE 107 AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 127
  • TABLE 108 AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 127
  • TABLE 109 AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 127
  • TABLE 110 AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 127
  • TABLE 111 SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 128
  • TABLE 112 SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 128
  • TABLE 113 SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 128
  • TABLE 114 SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 128
  • TABLE 115 THAILAND OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 129
  • TABLE 116 THAILAND OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 129
  • TABLE 117 THAILAND OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 129
  • TABLE 118 THAILAND OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 129
  • TABLE 119 MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 130
  • TABLE 120 MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 130
  • TABLE 121 MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 130
  • TABLE 122 MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 130
  • TABLE 123 INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 131
  • TABLE 124 INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 131
  • TABLE 125 INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 131
  • TABLE 126 INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 131
  • TABLE 127 PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 132
  • TABLE 128 PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 132
  • TABLE 129 PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 132
  • TABLE 130 PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 132
  • TABLE 131 REST OF ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 133
  • TABLE 132 REST OF ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 133
  • TABLE 133 REST OF ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 133
  • TABLE 134 REST OF ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 133
  • TABLE 135 SOUTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 138
  • TABLE 136 SOUTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 138
  • TABLE 137 SOUTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 138
  • TABLE 138 SOUTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 138
  • TABLE 139 SOUTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 139
  • TABLE 140 BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 140
  • TABLE 141 BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 140
  • TABLE 142 BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 140
  • TABLE 143 BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 140
  • TABLE 144 ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 141
  • TABLE 145 ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 141
  • TABLE 146 ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 141
  • TABLE 147 ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 141
  • TABLE 148 REST OF SOUTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 142
  • TABLE 149 MIDDLE EAST AND AFRICA OVARIAN CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 147
  • TABLE 150 MIDDLE EAST AND AFRICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 147
  • TABLE 151 MIDDLE EAST AND AFRICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 147
  • TABLE 152 MIDDLE EAST AND AFRICA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 147
  • TABLE 153 MIDDLE EAST AND AFRICA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 148
  • TABLE 154 SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 149
  • TABLE 155 SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 149
  • TABLE 156 SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 149
  • TABLE 157 SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 149
  • TABLE 158 SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 150
  • TABLE 159 SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 150
  • TABLE 160 SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 150
  • TABLE 161 SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 150
  • TABLE 162 U.A.E OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 151
  • TABLE 163 U.A.E OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 151
  • TABLE 164 U.A.E OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 151
  • TABLE 165 U.A.E OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 151
  • TABLE 166 EGYPT OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 152
  • TABLE 167 EGYPT OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 152
  • TABLE 168 EGYPT OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 152
  • TABLE 169 EGYPT OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 152
  • TABLE 170 ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 153
  • TABLE 171 ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 153
  • TABLE 172 ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 153
  • TABLE 173 ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 153
  • TABLE 174 REST OF MIDDLE EAST AND AFRICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 154

LIST OF FIGURES

  • FIGURE 1 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : SEGMENTATION 25
  • FIGURE 2 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : DATA TRIANGULATION 28
  • FIGURE 3 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : DROC ANALYSIS 29
  • FIGURE 4 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : GLOBAL VS REGIONAL MARKET ANALYSIS 30
  • FIGURE 5 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : COMPANY RESEARCH ANALYSIS 30
  • FIGURE 6 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : INTERVIEW DEMOGRAPHICS 32
  • FIGURE 7 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : DBMR MARKET POSITION GRID 33
  • FIGURE 8 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : MARKET TESTING TYPE COVERAGE GRID 34
  • FIGURE 9 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : VENDOR SHARE ANALYSIS 35
  • FIGURE 10 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : SEGMENTATION 39
  • FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT OVARIAN CANCER IS EXPECTED TO DRIVE THE GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2022 TO 2030 40
  • FIGURE 12 PRODUCT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET IN 2022 & 2030 40
  • FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET , AND ASIA-PACIFI IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030 41
  • FIGURE 14 EUROPE IS THE FASTEST-GROWING MARKET FOR GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030 42
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGE OF THE GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET 51
  • FIGURE 16 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022 59
  • FIGURE 17 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 60
  • FIGURE 18 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 60
  • FIGURE 19 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 61
  • FIGURE 20 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, 2022 65
  • FIGURE 21 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, 2023-2030 (USD MILLION) 66
  • FIGURE 22 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, CAGR (2023-2030) 66
  • FIGURE 23 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, LIFELINE CURVE 67
  • FIGURE 24 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022 73
  • FIGURE 25 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION) 74
  • FIGURE 26 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030) 74
  • FIGURE 27 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 75
  • FIGURE 28 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, 2022 79
  • FIGURE 29 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 80
  • FIGURE 30 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 80
  • FIGURE 31 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 81
  • FIGURE 32 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 87
  • FIGURE 33 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : BY COUNTRY (2022) 88
  • FIGURE 34 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : BY COUNTRY (2023 & 2030) 88
  • FIGURE 35 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 89
  • FIGURE 36 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET : BY PRODUCTS (2023-2030) 89
  • FIGURE 37 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 92
  • FIGURE 38 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 93
  • FIGURE 39 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 93
  • FIGURE 40 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 94
  • FIGURE 41 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030) 94
  • FIGURE 42 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 101
  • FIGURE 43 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 102
  • FIGURE 44 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 102
  • FIGURE 45 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 103
  • FIGURE 46 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030) 103
  • FIGURE 47 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 118
  • FIGURE 48 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 119
  • FIGURE 49 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 119
  • FIGURE 50 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 120
  • FIGURE 51 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030) 120
  • FIGURE 52 SOUTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 135
  • FIGURE 53 SOUTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 136
  • FIGURE 54 SOUTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 136
  • FIGURE 55 SOUTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 137
  • FIGURE 56 SOUTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030) 137
  • FIGURE 57 MIDDLE EAST AND AFRICA OVARIAN CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 144
  • FIGURE 58 MIDDLE EAST AND AFRICA OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 145
  • FIGURE 59 MIDDLE EAST AND AFRICA OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 145
  • FIGURE 60 MIDDLE EAST AND AFRICA OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 146
  • FIGURE 61 MIDDLE EAST AND AFRICA OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030) 146
  • FIGURE 62 GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 155
  • FIGURE 63 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 156
  • FIGURE 64 EUROPE OVARIAN CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 157
  • FIGURE 65 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 158
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!